科兴生物制药股份有限公司 信息披露暂缓与豁免事务管理制度 信息批 科兴生物制药股份有限公司 第一章 总则 第一条 为规范科兴生物制药股份有限公司（以下简称"公司"）的信息披露暂缓与豁免 行为，督促公司及相关信息披露义务人（以下简称"信息披露义务人"）依法、合规地履行信 息披露义务，保护投资者的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券 法》、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、上海证券交 易所《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》（以下简称"《规 范运作》"）《上市公司信息披露暂缓与豁免管理规定》等法律、法规、规章和《科兴生物制 药股份有限公司章程》（以下简称"《公司章程》"）、《科兴生物制药股份有限公司信息披 露管理制度》（以下简称"《信息披露管理制度》"）等内部制度的有关规定，结合公司实际 情况，制定本制度。 第二条 信息披露义务人按照《上市规则》、《规范运作》及其他相关法律、法规、规范 性文件的规定，办理信息披露暂缓、豁免业务的，适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地披露信息，不 得滥用暂缓或 ...

General Principles - The document outlines the management system for the shares held by directors and senior management of Sinovac Biotech Ltd, aiming to strengthen the declaration, disclosure, supervision, and management of their stock trading activities [1][2] - The system is established in accordance with various laws and regulations, including the Company Law and Securities Law of the People's Republic of China, as well as the company's articles of association [1] Share Trading Regulations - Directors and senior management must be aware of and comply with laws prohibiting insider trading, market manipulation, and short-term trading before buying or selling company shares [2] - They are encouraged to stabilize stock prices by purchasing shares during significant price declines [2] - Directors and senior management are prohibited from engaging in margin trading or derivative transactions involving the company's stock [2][3] Share Transfer Restrictions - There are specific conditions under which shares held by directors and senior management cannot be transferred, including within one year of the company's stock listing and within six months after leaving the company [3][4] - Additional restrictions apply if the company is under investigation for securities violations or if the directors and senior management have been penalized for such violations [4] Shareholding and Transfer Management - Core technical personnel are subject to additional restrictions on transferring shares acquired before the company's initial public offering, including a 12-month lock-up period and annual transfer limits [4][5] - Directors and senior management must notify the board secretary of their trading plans in writing, and the secretary must verify the appropriateness of the transaction [3][5] Disclosure Requirements - Directors and senior management must disclose any changes in their shareholdings within two trading days of the change, including details such as the number of shares before and after the change, the date, and the price [6][16] - They are also required to report their personal information to the company and the stock exchange at specified times, including upon appointment and when there are changes [16][19] Compliance and Accountability - The company and its directors and senior management must ensure that all information related to shareholding and transfer is timely, truthful, accurate, and complete, bearing legal responsibility for any discrepancies [19] - The board secretary is responsible for managing the data and information related to directors and senior management's shareholdings and must report any violations to regulatory authorities [19]

Core Points - The articles outline the articles of association for Kexing Biopharm Co., Ltd., detailing the company's legal framework, governance structure, and operational guidelines [2][4][5]. Group 1: General Provisions - The company is established as a joint-stock limited company in accordance with the Company Law and other relevant regulations [2][3]. - The registered capital of the company is RMB 201,257,250.00 [3]. - The company is permanently established and has its legal representative as the chairman [3][4]. Group 2: Business Objectives and Scope - The company's mission is to promote the development of high-quality biopharmaceuticals and enhance their clinical value, focusing on safety and reliability for patients [5]. - The business scope includes research, production, and sales of biological products, chemical drugs, raw materials, and traditional Chinese medicine, among others [5]. Group 3: Shares - The company has issued a total of 201,257,250 shares, all of which are ordinary shares denominated in RMB [6][20]. - The issuance of shares follows principles of openness, fairness, and justice, ensuring equal rights for all shares of the same category [6][7]. Group 4: Shareholder Rights and Responsibilities - Shareholders have rights to dividends, attend meetings, supervise the company, and access company documents [13][34]. - Shareholders are obligated to comply with laws and regulations, pay for their subscribed shares, and not abuse their rights to harm the company or other shareholders [40][41]. Group 5: Shareholder Meetings - The company holds annual and temporary shareholder meetings, with the annual meeting required to be held within six months after the end of the fiscal year [21][52]. - Shareholder meetings can be convened by the board of directors or at the request of shareholders holding more than 10% of the shares [56][61]. Group 6: Decision-Making and Voting - Major decisions, such as capital increases, mergers, and significant asset transactions, require approval from the shareholders' meeting [21][49]. - Voting procedures and requirements for decision-making are clearly defined, ensuring transparency and accountability [30][34].

科兴生物制药股份有限公司 目 录 第一章 总 则 第一条 为规范科兴生物制药股份有限公司（以下简称"公司"）的关联交易， 保证公司关联交易的公允性，维护公司及公司全体股东的合法权益，根据《中华 人民共和国公司法》（以下称"《公司法》"）《企业会计准则第 36 号——关联方 披露》《上海证券交易所科创板股票上市规则》（以下简称"《科创板股票上市规 科兴生物制药股份有限公司 （修订稿） 二〇二五年七月 《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》等 则》"） 有关法律法规及《科兴生物制药股份有限公司章程》（以下称"《公司章程》"） 的有关规定，结合公司实际情况，制订本制度。 第二条 本制度对公司股东、董事和高级管理人员具有约束力，公司股东、 董事和高级管理人员必须遵守。 第三条 公司关联交易应当定价公允、决策程序合规、信息披露规范，保证 关联交易的合法性、必要性、合理性和公允性，保持公司的独立性，不得利用关 联交易调节财务指标，损害公司利益。 第四条 关联交易活动应遵循以下基本原则： （一）平等、自愿、等价、有偿的原则； （二）公平、公正、公开的原则； （三）不损害公司及非关联股东合法权益的 ...

有关规定，结合公司实际情况，制定本细则。 科兴生物制药股份有限公司 二〇二五年七月 科兴生物制药股份有限公司 第一章 总 则 第一条 为规范科兴生物制药股份有限公司（以下简称"公司"或"本公司"） 总经理、副总经理及其他高级管理人员的管理水平和管理效率，进一步规范公司 总经理、副总经理及其他高级管理人员的议事方式和决策程序，保证总经理、副 总经理及其他高级管理人员能够合法有效地履行其职责，根据《中华人民共和国 公司法》、《中华人民共和国证券法》、《上市公司治理准则》、《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、法规、规 范性文件以及《科兴生物制药股份有限公司章程》 （以下简称"《公司章程》"）的 第二条 本细则所称高级管理人员是指公司的总经理、副总经理、财务总监、 董事会秘书和《公司章程》规定的其他人员。 第三条 公司依法设置总经理一名，总经理由董事长提名，并由董事会批准 后聘任或解聘。总经理主持公司日常经营活动和管理工作组织，负责组织实施董 事会决议，对董事会负责。 公司设置其他高级管理人员若干名，协助总经理工作。其他高级管理人员是 指公司的副总经理、董事会秘书、财务总监 ...

科兴生物制药股份有限公司 信息披露管理制度 规定，结合公司的实际情况，特制定本制度。 第二条 本制度所称信息披露，是当发生或即将发生可能对公司证券及其衍 生品的交易价格产生较大影响或者对投资决策有较大影响的信息以及证券监管 部门要求或公司主动披露的信息（以下简称"重大信息"）时，根据法律、法规、 规范性文件的规定及时将相关信息的公告文稿和相关备查文件报送上海证券交 易所登记，并在上海证券交易所网站和符合中国证券监督管理委员会（以下简称 "中国证监会"）规定条件的媒体上（以下统称"符合条件媒体"）发布。 第三条 本制度所称重大信息是指公司依法发布的定期报告及其他可能对公 司证券及其衍生品种价格产生较大影响的信息。 科兴生物制药股份有限公司 二〇二五年七月 目 录 科兴生物制药股份有限公司 第一章 总则 第一条 为确保科兴生物制药股份有限公司（以下简称"公司"）信息披露的 及时、准确、充分、完整，保护投资者合法权益，根据《中华人民共和国公司法》、 《上市公司信息披露管理办法》（以下简称"《管理办法》"）、《上海证券交易所 科创板股票上市规则》（以下简称"《科创板上市规则》"）等法律、法规、规范 性文件及《科兴生物 ...

科兴生物制药股份有限公司 （修订稿） 二〇二五年七月 科兴生物制药股份有限公司 目 录 第一章 总则 第一条 为规范科兴生物制药股份有限公司（以下简称"公司"）的内幕信息 管理，维护信息披露的公平原则，完善内、外部信息知情人管理事 务，避免及防范内幕信息知情人滥用知情权，进行内幕交易，根据 《中华人民共和国公司法》《中华人民共和国证券法》《上市公司信 《上市公司监管指引第 5 号——上市公司内幕信息 息披露管理办法》 第二章 内幕信息和内幕信息知情人 程》（以下简称"《公司章程》"）、《科兴生物制药股份有限公司 信息披露管理制度》的规定，制定本制度。 第二条 本制度适用于公司各部门、分公司、控股子公司以及本公司能够实 施重大影响的参股公司。 第三条 非内幕信息知情人自知悉内幕信息后即成为内幕信息知情人，受本 制度约束，直至此等信息公开披露。 第四条 公司董事会是内幕信息的管理机构，董事会保证内幕知情人档案真 实、准确和完整，董事长为主要责任人。董事会秘书负责公司内幕 信息监管和内幕信息知情人的档案登记工作。董事会办公室协助董 事会秘书做好内幕信息登记管理的日常工作。公司审计委员会对内 幕信息知情人登记管理制度 ...

Core Viewpoint - The company aims to establish a robust investor relations management system to enhance communication with investors, protect their rights, and improve corporate governance and overall value [1][3]. Group 1: Principles and Objectives of Investor Relations Management - The investor relations management should adhere to principles of compliance, equality, proactivity, honesty, efficiency, and interactive communication [2][3]. - The primary objectives include fostering a positive relationship with investors, building a stable investor base, promoting a culture of respect for investors, maximizing overall corporate benefits, and increasing transparency in information disclosure [3][4]. Group 2: Communication and Disclosure Practices - The company will communicate key information regarding its development strategy, financial status, and significant events through various channels, including regular reports, shareholder meetings, and the company website [4][6]. - The company is committed to timely and fair information disclosure, ensuring that all communications are clear, accurate, and devoid of misleading statements [8][10]. Group 3: Organizational Structure and Responsibilities - The board secretary is designated as the head of investor relations management, overseeing daily operations and ensuring compliance with relevant regulations [11][12]. - The company will maintain a database for investor relations management, documenting all activities and communications to ensure transparency and accountability [13][14].

Core Points - The company establishes a remuneration and assessment committee to enhance governance structure and manage the compensation of directors and senior management [1][2] - The committee consists of three directors, including two independent directors, and is responsible for formulating and reviewing compensation policies and assessment standards [2][3] - The committee's decisions must be submitted to the board for approval, and any non-accepted recommendations must be documented with reasons [3][4] Group 1 - The remuneration and assessment committee is tasked with developing assessment standards for directors and senior management, as well as reviewing compensation mechanisms [3][4] - The committee's decisions are subject to board approval and must be disclosed if not fully adopted [3][7] - The committee is supported by the company's human resources center, which provides necessary operational data and performance metrics [4][5] Group 2 - The committee meetings require a two-thirds attendance of members to be valid, and decisions are made by majority vote [6][7] - Meeting records must include details such as date, attendees, agenda, and voting results, and are kept as company archives [7][8] - The committee has the authority to invite other directors and senior management to meetings for reporting or questioning [6][7]

Core Viewpoint - The document outlines the governance structure and operational guidelines for the Board Secretary of Sinovac Biotech Ltd, emphasizing the importance of compliance with legal and regulatory frameworks [1][2][3]. Group 1: General Provisions - The document establishes the purpose of the guidelines, which is to regulate the behavior of the Board Secretary and enhance corporate governance [1]. - It defines the Board Secretary as a senior management position responsible for legal obligations and duties as per laws and company regulations [2]. - The Board Secretary acts as the designated liaison between the company and regulatory bodies, handling information disclosure and corporate governance matters [2][3]. Group 2: Qualifications and Conditions - The qualifications for the Board Secretary include a minimum of a college degree and at least three years of relevant experience in secretarial, management, or equity affairs [3]. - Candidates must possess knowledge in finance, law, and corporate management, and must adhere to ethical standards [3]. - Individuals with certain disqualifying conditions, such as recent administrative penalties from regulatory bodies, are prohibited from serving as Board Secretary [3]. Group 3: Appointment and Replacement - The Board Secretary is appointed or dismissed by the company's Board of Directors, and a securities affairs representative must be appointed to assist [4][5]. - The company must publicly announce the appointment of the Board Secretary and securities affairs representative, providing necessary documentation [4]. - The company is required to have valid reasons for dismissing the Board Secretary and must report the dismissal to the regulatory authority [5]. Group 4: Responsibilities and Duties - The Board Secretary is responsible for managing information disclosure, investor relations, and equity management [6]. - Duties include organizing board meetings, maintaining confidentiality of sensitive information, and ensuring compliance with legal obligations [6]. - The Board Secretary must also facilitate training for board members regarding their rights and responsibilities in information disclosure [6]. Group 5: Miscellaneous Provisions - The document states that the guidelines will be effective upon approval by the Board of Directors and will be subject to relevant laws and regulations [7]. - The Board of Directors holds the authority to amend and interpret these guidelines as necessary [7].